VIDEO: Recent studies offer insights for perioperative lung cancer
Click Here to Manage Email Alerts
Healio spoke with Charu Aggarwal, MD, MPH, about results from the Keynote-671 trial presented at this year’s ASCO Annual Meeting.
Aggarwal, who is the Lesley M. Heisler assistant professor for lung cancer excellence at University of Pennsylvania's Perelman School of Medicine and a HemOnc Today Editorial Board Member, also discussed results from the AEGEAN trial recently presented at American Association for Cancer Research Annual Meeting.
The trials assessed the use of neoadjuvant chemotherapy in addition to ongoing immunotherapy.
“I think both trials are demonstrating an improvement in [pathologic complete responses (pCRs)] with the combination of chemoimmunotherapy as well as an improvement in EFS, or event-free survival, and early signals — very early — that overall survival may be improved as well,” Aggarwal said.
She added that while these trials “raise many questions” about how to manage postoperative patients, they “are important because they are adding to our understanding of the use of immunotherapy, both before and after surgery.”
References:
- Heymach JV, et al. Abstract CT005. Presented at: American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando.
- Wakelee H, et al. Abstract LBA100. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Collapse
Healio Interview
Read more about
Click Here to Manage Email Alerts